Eli Lilly says its Alzheimer's treatment reduces plaque

Eli Lilly Co. LLY said on Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and Biogen's Aduhelm in a Phase 3 clinical trial. Amyloid plaque is a biomarker associated with Alzheimer's. Aduhem had plaque clearance of 1.6%, while Lilly's drug, donanemab, reduced amyloid plaque by 37.9%. The study, which compared the treatments in patients with early symptomatic Alzheimer's disease, met the primary and secondary endpoints after six months. The Food and Drug Administration is one of five studies that will be used to submit a submission to the Food and Drug Administration for approval of donanemab. David Risinger, SVB Securities analyst, told investors on Thursday morning that the disclosure is incrementally positive and that the donab will have an impact on cognition. Lilly's stock has gone up 34.3% this year, while the S&P 500 SPX has declined 14.4%.